The FDA has given emergency authorization to a “bivalent” vaccine that targets the original COVID-19 virus, along with the world-dominate BA.4 and BA.5 variants. The new combination booster is expected to provide similar or better protection against omicron.

The Advisory Committee for Immunization Practices (ACIP) is expected to vote September 1, 2022 on a recommendation for who should receive the boosters and when.

Get up-to-date information on COVID-19 vaccines and more by using the NCDHHS’s COVID-19 Dashboard.